Reboxetine: the first selective noradrenaline re-uptake inhibitor

Several treatment approaches are available for treatment of depression. However, reboxetine is the first selective noradrenaline re-uptake inhibitor. Whereas formerly only noradrenaline re-uptake inhibitors with a mixed mechanism of action were available. These included action not only at noradrenergic, but also at serotonergic and other neurotransmitter-sites. Thus, reboxetine represents the first of a new class of antidepressant agents with specificity for the noradrenergic system. Reboxetine has been shown to be an effective first-line treatment for patients with all grades of depression, to be effective in the prevention of relapse and recurrence and to offer significant benefits in terms of relieving the impaired social functioning associated with depressive disorders. Reboxetine was significantly superior to the serotonergic compound fluoxetine in improvement of social functioning in both the general depressed population and in those patients who achieved symptomatic remission, indicating a superior quality of remission. Altogether reboxetine was well tolerated during the acute and long-term treatment phase; side-effects such as increased sweating, constipation and dry mouth were the most prominent to be reported. The availability of reboxetine represents a significant addition to the currently available pharmacologic armamentarium for the treatment of depression.

[1]  R. Poland,et al.  Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents , 2001, Psychopharmacology.

[2]  M B Keller,et al.  Social functioning in depression: a review. , 2000, The Journal of clinical psychiatry.

[3]  C. Katona,et al.  Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial. , 1999, Journal of affective disorders.

[4]  P. Gaszner,et al.  Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. , 1999, The Journal of clinical psychiatry.

[5]  H. Möller,et al.  Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. , 1999, International clinical psychopharmacology.

[6]  C. Spencer,et al.  Reboxetine: A Review of its Use in Depression , 1999 .

[7]  R. Cookson,et al.  The economic value of atypical antipsychotics: A comparison of risperidone and olanzapine revisited. , 1999, International journal of psychiatry in clinical practice.

[8]  I. Poggesi,et al.  Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics. , 1999, Biopharmaceutics & drug disposition.

[9]  W. Herrmann,et al.  Reboxetine, a selective noradrenaline reuptake inhibitor, is non‐sedative and does not impair psychomotor performance in healthy subjects , 1998 .

[10]  I. Hindmarch.  Editorial. It's all in the Mind: Measuring Somnolence and CNS Drug Side Effects , 1998 .

[11]  I. Hindmarch.  Effect of antidepressants on cognitive and psychomotor function: the lack of effect of reboxetine , 1998 .

[12]  E. Szabadi,et al.  Reboxetine in the treatment of depression: Early clinical experience in the UK. , 1998, International journal of psychiatry in clinical practice.

[13]  W. Rein,et al.  Clinical update on amisulpride in deficit schizophrenia , 1997, International clinical psychopharmacology.

[14]  A. Dubini,et al.  Do noradrenaline and serotonin differentially affect social motivation and behaviour? , 1997, European Neuropsychopharmacology.

[15]  I. Poggesi,et al.  Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor , 1997, European Neuropsychopharmacology.

[16]  S. Kasper,et al.  Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. , 1997, Journal of clinical psychopharmacology.

[17]  C. Gagiano,et al.  Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes , 1997, European Neuropsychopharmacology.

[18]  A. Dubini,et al.  Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale , 1997, European Neuropsychopharmacology.

[19]  J. Lépine,et al.  Depression in the community: the first pan‐European study DEPRES (Depression Research in European Society) , 1997, International clinical psychopharmacology.

[20]  M. Mucci.  Reboxetine: a review of antidepressant tolerability. , 1997, Journal of psychopharmacology.

[21]  S. Montgomery.  Reboxetine: additional benefits to the depressed patient. , 1997, Journal of psychopharmacology.

[22]  A. Dubini,et al.  Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. , 1997, Journal of psychopharmacology.

[23]  B. Pollock,et al.  Dr. Nemeroff and Colleagues Reply , 1996 .

[24]  B. Pollock,et al.  Newer antidepressants and the cytochrome P450 system. , 1996, The American journal of psychiatry.

[25]  Germany,et al.  Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding , 1995, Biopharmaceutics & drug disposition.

[26]  Clinical relevance of response and improvement in psychopharmacology: European College of Neuropsychopharmacology. , 1995, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.

[27]  A. Nierenberg.  The treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generations? , 1994, The Journal of clinical psychiatry.

[28]  M. Keller.  The long-term treatment of depression. , 1994, The Journal of clinical psychiatry.

[29]  I. Anderson,et al.  The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants , 1994, Journal of psychopharmacology.

[30]  R. Kessler,et al.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. , 1994, Archives of general psychiatry.

[31]  Riva,et al.  Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: Behavioural and biochemical studies , 1989 .

[32]  E. Paykel,et al.  Social adjustment and depression. A longitudinal study. , 1973, Archives of general psychiatry.